Abbott’s Epic Plus Tissue Valves Receives the US FDA’s Approval for the Treatment of Mitral or Aortic Valve Replacement

 Abbott’s Epic Plus Tissue Valves Receives the US FDA’s Approval for the Treatment of Mitral or Aortic Valve Replacement

Shots:

  • The US FDA has approved Abbott’s Epic Plus & Epic Plus Supra Stented Tissue valves to treat patients with aortic or MV disease who undergoes valve replacement surgery. The devices build off Abbott’s Epic surgical valve platform
  • Abbott’s Epic valve including radiopaque markers helps to improve implantation & allows compatibility for future transcatheter valve procedures. The new valves are designed to deliver long-term performance & durability due to Abbott’s anti calcification technology
  • The Epic Plus Mitral holder helps to certify a precise insertion of the valve. The device can be implanted in the aortic or mitral valve position & in patients with complicated anatomies

Click here to­ read full press release/ article | Ref: Abbott | Image: The Street

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post